Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer

ALK, n=2; RET, n=1; ROS1, n=1). Clinicopathologic features were used to determine whether these cases had true gene rearrangement. All cases had adenocarcinoma histology and no or little smoking history, which is consistent with true gene-rearranged NSCLC. Next-generation sequencing (NGS, CD74-ROS1) and nanostring technology (KIF5B-RET) were used to identify fusion partners in two cases. The ROS1 and RET cases received the robust clinical benefit of ICI and had immunotherapy PFS of 36 and 8 months, respectively. Only immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) was used to diagnose two ALK cases. In patients with ALK

[1]  J. Mazières,et al.  PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer—an IMMUNOTARGET case series , 2022, Translational lung cancer research.

[2]  E. Handorf,et al.  Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy , 2022, Journal of Cancer Research and Clinical Oncology.

[3]  Y. Hosomi,et al.  Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations , 2022, Thoracic cancer.

[4]  Y. Lou,et al.  Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR , 2021, Frontiers in Oncology.

[5]  M. Socinski,et al.  IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  S. Digumarthy,et al.  Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers , 2021, JTO clinical and research reports.

[7]  B. Besse,et al.  PUL01.02 AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion+ Advanced/Metastatic NSCLC , 2021, Journal of Thoracic Oncology.

[8]  C. Langer,et al.  Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer. , 2020, Clinical lung cancer.

[9]  Jiayi Shen,et al.  Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  M. Copin,et al.  Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma. , 2020, Lung cancer.

[11]  T. Hida,et al.  Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement , 2020, International journal of molecular sciences.

[12]  J. Ahn,et al.  Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. , 2020, Japanese journal of clinical oncology.

[13]  R. Riedel,et al.  Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors. , 2019, Journal of Molecular Diagnostics.

[14]  A. Drilon,et al.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Ladanyi,et al.  Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers , 2019, JCO precision oncology.

[16]  A. Drilon,et al.  Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  A. Allen,et al.  Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). , 2018, Lung cancer.

[18]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  V. Gebski,et al.  Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[21]  Y. Yatabe.  ALK FISH and IHC: you cannot have one without the other. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  A. Drilon,et al.  Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer , 2021 .

[23]  Edward S. Kim,et al.  P87.02 AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion+ Advanced/Metastatic NSCLC , 2021, Journal of Thoracic Oncology.